NGEN NERVGEN PHARMA CORP.
Price Chart
Executive Summary
NervGen announced positive independent, blinded biomechanical gait analyses from the Phase 1b/2a CONNECT SCI study, demonstrating statistically significant improvement in gait quality (p=0.0197) with NVG-291 versus placebo. 100% of NVG-291 subjects were classified as responders versus 10% for placebo (p=0.0001). The company is on track to initiate the Phase 3 RESTORE registrational study in mid-2026.
Actionable Insight
These biomechanical gait results provide strong independent, objective evidence of genuine neural recovery, significantly de-risking the upcoming Phase 3 RESTORE study. With the stock at ~$171M market cap and positive Phase 1b/2a data across multiple domains (electrophysiology, functional hand use, QoL, and now gait), NVG-291 has potential as a first-in-class therapy for chronic tetraplegia. Monitor for site activation and patient enrollment milestones for RESTORE in mid-2026.
Key Facts
- NVG-291 demonstrated statistically significant improvement in gait quality (GTE=+0.45; 95% CI: +0.15 to +0.72; p=0.0197)
- 100% (10/10) of NVG-291 subjects classified as responders vs 10% (1/10) for placebo (p=0.0001)
- Speed-effort dissociation shows speed gains driven by restored neural control, not compensation
- Consistent statistically significant benefit across all three recovery measures: coordination (p=0.007), mechanical effort (p=0.038), postural stability (p=0.044)
- Company on track to initiate Phase 3 RESTORE registrational study in mid-2026 with site activation underway
- FDA Fast Track and EMA Orphan Drug designations for NVG-291 for SCI treatment
Financial Impact
No financial figures provided in filing; pre-revenue clinical-stage biopharma. Positive Phase 1b/2a results de-risk Phase 3 and increase probability of regulatory approval and commercial value.
Risk Factors
- Phase 3 clinical trials may fail to replicate Phase 1b/2a results
- Pre-revenue company needs additional financing to complete Phase 3
- Regulatory approval not guaranteed even with positive data
- Competition from other SCI therapies in development
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-066307 |
| Document: tm2615621d1_6k.htm | 0001104659-26-066307 |
| Document: 0001104659-26-066307-index-headers.html | 0001104659-26-066307 |
| Document: 0001104659-26-066307-index.html | 0001104659-26-066307 |
| Document: 0001104659-26-066307.txt | 0001104659-26-066307 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
11d ago
|
6-K
| $2.00 $1.91 | ▲ +4.50% | ▲ +3.78% | $1.92 (+4.00%) |
|
May 27, 2026
17d ago
|
EFFECT
| $2.07 $2.08 | ▲ +0.48% | ▼ −0.07% | $1.92 (−7.25%) |
|
May 26, 2026
17d ago
|
6-K
| $2.07 $2.08 | ▲ +0.48% | ▼ −0.06% | $1.92 (−7.25%) |
|
May 22, 2026
21d ago
|
6-K
| $2.13 $2.07 | ▲ +2.82% | ▲ +2.83% | $1.92 (+9.86%) |
|
May 22, 2026
22d ago
|
Press Release
| $2.08 $2.13 | ▼ −2.40% | ▼ −1.82% | $1.92 (+7.69%) |
|
May 21, 2026
22d ago
|
Press Release
| $2.08 $2.13 | ▼ −2.40% | ▼ −1.82% | $1.92 (+7.69%) |
|
May 18, 2026
25d ago
|
6-K
| $3.56 $3.74 | ▲ +5.06% | ▲ +4.02% | $1.92 (−46.07%) |
|
May 18, 2026
26d ago
|
Press Release
| $3.64 $3.56 | ▲ +2.20% | ▲ +1.55% | $1.92 (+47.25%) |
|
Apr 27, 2026
6w ago
|
6-K
| $3.88 $3.75 | ▼ −3.41% | ▼ −3.40% | $1.92 (−50.52%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $3.77 $4.36 | ▲ +15.65% | ▲ +14.90% | $1.92 (−49.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access